Trident Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 28, 2025, 7:29 pm

Competitors of Trident Ltd

All Competitor Stocks of Trident Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:00 am

Below is a detailed analysis of the quarterly data for Trident Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,707.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,864.00 Cr. (Mar 2025) to 1,707.00 Cr., marking a decrease of 157.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,415.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,619.00 Cr. (Mar 2025) to 1,415.00 Cr., marking a decrease of 204.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 292.00 Cr.. The value appears strong and on an upward trend. It has increased from 245.00 Cr. (Mar 2025) to 292.00 Cr., marking an increase of 47.00 Cr..
• For OPM %, as of Jun 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 13.00% (Mar 2025) to 17.00%, marking an increase of 4.00%.
• For Other Income, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 31.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 28.00 Cr..
• For Depreciation, as of Jun 2025, the value is 93.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 90.00 Cr. (Mar 2025) to 93.00 Cr., marking an increase of 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 188.00 Cr.. The value appears strong and on an upward trend. It has increased from 172.00 Cr. (Mar 2025) to 188.00 Cr., marking an increase of 16.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 25.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 133.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 7.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.27. The value appears strong and on an upward trend. It has increased from 0.26 (Mar 2025) to 0.27, marking an increase of 0.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:14 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: August 11, 2025, 3:00 pm

Below is a detailed analysis of the balance sheet data for Trident Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 510.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 510.00 Cr..
• For Reserves, as of Mar 2025, the value is 4,111.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,806.00 Cr. (Mar 2024) to 4,111.00 Cr., marking an increase of 305.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,635.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,126.00 Cr. (Mar 2024) to 1,635.00 Cr., marking a decrease of 491.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 904.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,122.00 Cr. (Mar 2024) to 904.00 Cr., marking a decrease of 218.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 7,161.00 Cr.. The value appears to be improving (decreasing). It has decreased from 7,563.00 Cr. (Mar 2024) to 7,161.00 Cr., marking a decrease of 402.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 4,455.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,608.00 Cr. (Mar 2024) to 4,455.00 Cr., marking a decrease of 153.00 Cr..
• For CWIP, as of Mar 2025, the value is 53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 88.00 Cr. (Mar 2024) to 53.00 Cr., marking a decrease of 35.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 49.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,653.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,819.00 Cr. (Mar 2024) to 2,653.00 Cr., marking a decrease of 166.00 Cr..
• For Total Assets, as of Mar 2025, the value is 7,161.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,563.00 Cr. (Mar 2024) to 7,161.00 Cr., marking a decrease of 402.00 Cr..

Notably, the Reserves (4,111.00 Cr.) exceed the Borrowings (1,635.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Trident Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has increased from 0.69 (Mar 24) to 0.73, marking an increase of 0.04.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has increased from 0.69 (Mar 24) to 0.73, marking an increase of 0.04.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 3. It has increased from 1.40 (Mar 24) to 1.45, marking an increase of 0.05.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 9.07. It has increased from 8.47 (Mar 24) to 9.07, marking an increase of 0.60.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 9.07. It has increased from 8.47 (Mar 24) to 9.07, marking an increase of 0.60.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 13.71. It has increased from 13.36 (Mar 24) to 13.71, marking an increase of 0.35.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 2. It has decreased from 1.96 (Mar 24) to 1.91, marking a decrease of 0.05.
• For PBIT / Share (Rs.), as of Mar 25, the value is 1.19. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.19, marking a decrease of 0.05.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.93. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.93.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.72. This value is below the healthy minimum of 2. It has increased from 0.68 (Mar 24) to 0.72, marking an increase of 0.04.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.72. This value is below the healthy minimum of 2. It has increased from 0.68 (Mar 24) to 0.72, marking an increase of 0.04.
• For PBDIT Margin (%), as of Mar 25, the value is 13.89. This value is within the healthy range. It has decreased from 14.65 (Mar 24) to 13.89, marking a decrease of 0.76.
• For PBIT Margin (%), as of Mar 25, the value is 8.65. This value is below the healthy minimum of 10. It has decreased from 9.29 (Mar 24) to 8.65, marking a decrease of 0.64.
• For PBT Margin (%), as of Mar 25, the value is 6.79. This value is below the healthy minimum of 10. It has decreased from 7.00 (Mar 24) to 6.79, marking a decrease of 0.21.
• For Net Profit Margin (%), as of Mar 25, the value is 5.30. This value is within the healthy range. It has increased from 5.14 (Mar 24) to 5.30, marking an increase of 0.16.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.29. This value is below the healthy minimum of 8. It has increased from 5.13 (Mar 24) to 5.29, marking an increase of 0.16.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.00. This value is below the healthy minimum of 15. It has decreased from 8.09 (Mar 24) to 8.00, marking a decrease of 0.09.
• For Return on Capital Employeed (%), as of Mar 25, the value is 10.23. This value is within the healthy range. It has decreased from 10.80 (Mar 24) to 10.23, marking a decrease of 0.57.
• For Return On Assets (%), as of Mar 25, the value is 5.16. This value is within the healthy range. It has increased from 4.62 (Mar 24) to 5.16, marking an increase of 0.54.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.27 (Mar 24) to 0.20, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. There is no change compared to the previous period (Mar 24) which recorded 0.94.
• For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.01, marking an increase of 0.43.
• For Quick Ratio (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has increased from 0.76 (Mar 24) to 1.01, marking an increase of 0.25.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.30. This value is within the healthy range. It has decreased from 5.50 (Mar 24) to 5.30, marking a decrease of 0.20.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 48.97. This value is within the healthy range. It has decreased from 51.82 (Mar 24) to 48.97, marking a decrease of 2.85.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 24.61. This value is within the healthy range. It has decreased from 25.35 (Mar 24) to 24.61, marking a decrease of 0.74.
• For Earning Retention Ratio (%), as of Mar 25, the value is 51.03. This value is within the healthy range. It has increased from 48.18 (Mar 24) to 51.03, marking an increase of 2.85.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 75.39. This value exceeds the healthy maximum of 70. It has increased from 74.65 (Mar 24) to 75.39, marking an increase of 0.74.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 7.46. This value is within the healthy range. It has increased from 6.38 (Mar 24) to 7.46, marking an increase of 1.08.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.85. This value is within the healthy range. It has increased from 3.24 (Mar 24) to 3.85, marking an increase of 0.61.
• For Enterprise Value (Cr.), as of Mar 25, the value is 13,262.52. It has decreased from 20,152.65 (Mar 24) to 13,262.52, marking a decrease of 6,890.13.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 2.96 (Mar 24) to 1.90, marking a decrease of 1.06.
• For EV / EBITDA (X), as of Mar 25, the value is 13.66. This value is within the healthy range. It has decreased from 20.19 (Mar 24) to 13.66, marking a decrease of 6.53.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 1.77, marking a decrease of 0.96.
• For Retention Ratios (%), as of Mar 25, the value is 51.02. This value is within the healthy range. It has increased from 48.17 (Mar 24) to 51.02, marking an increase of 2.85.
• For Price / BV (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has decreased from 4.31 (Mar 24) to 2.68, marking a decrease of 1.63.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 1.77, marking a decrease of 0.96.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness